分子標的治療の世界市場レポート2025年

分子標的治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.5％で994億米ドルに成長します。予測期間中の成長は、がん研究への投資拡大、標的免疫療法への需要拡大、精密医療における臨床試験活動の拡大、コンパニオン診断薬の利用拡大、新興市場におけるヘルスケアアクセスの改善によって促進されると予測されます。予測期間中に予想される主な動向には、ゲノミクスの進歩、ドラッグデリバリーシステムの革新、研究開発資金の増加、分子診断の進歩、治療法の発見におけるAI技術の統合などがあります。

個別化医療の台頭は、今後の分子標的治療市場の成長を促進すると予想されます。個別化医療とは、個人の遺伝子プロファイル、ライフスタイル、環境要因に基づいて治療や予防をカスタマイズするヘルスケアアプローチです。このアプローチは、遺伝子データの利用可能性の増加により、有効性の向上と副作用の軽減のために個人のゲノムに合わせた治療が可能になり、支持を集めています。個別化医療は、患者の腫瘍を分析して特定の遺伝子変異やバイオマーカーを検出し、それらの異常を直接標的とする治療を選択できるようにすることで、分子標的治療をサポートします。これにより治療の精度が高まり、健康な組織への害が最小限に抑えられます。例えば、2024年2月、米国の病院・ヘルスケア団体である個別化医療連合（Personalized Medicine Coalition）は、FDAが2023年に希少疾患患者のために新たに承認した個別化治療は16件で、2022年の6件から増加したと報告しました。したがって、個別化医療の台頭が分子標的治療市場の成長を牽引しています。

分子標的治療市場で事業を展開する主要企業は、様々ながんや慢性疾患における患者の転帰を改善するため、低分子阻害剤などの先進製品の開発に注力しています。低分子阻害剤は、細胞に浸透し、疾患の進行を促進する特定のタンパク質を阻害することができる小さな化合物です。例えば、2025年1月、米国の製薬会社であるアムジェン社は、ベクティビックス（パニツムマブ）と併用するルマクラス（ソトラシブ）を発表し、米国の政府機関である米国食品医薬品局（FDA）から承認を取得しました。この治療法は、FDAが承認した検査で確認された、フルオロピリミジン、オキサリプラチン、イリノテカンをベースとした化学療法を受けたことのあるKRAS G12C変異転移性大腸がんの成人患者を対象としています。今回の承認は、第3相CodeBreaK 300試験の結果に基づいており、この併用療法は標準治療と比較して無増悪生存期間を2倍以上延長することが示され、化学療法抵抗性のこの患者群でこのような結果を達成した初めての標的療法となりました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の分子標的治療：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の分子標的治療市場：成長率分析
• 世界の分子標的治療市場の実績：規模と成長, 2019-2024
• 世界の分子標的治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界の分子標的治療：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の分子標的治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 低分子阻害剤
• 遺伝子治療
• 細胞療法
• 世界の分子標的治療市場投与方法別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• トピック
• 静脈内
• 世界の分子標的治療市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肺がん
• 乳がん
• 大腸がん
• 白血病
• その他の用途
• 世界の分子標的治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 調査室
• 診断センター
• 世界の分子標的治療市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 裸のモノクローナル抗体
• 結合モノクローナル抗体
• 二重特異性モノクローナル抗体
• 世界の分子標的治療市場低分子阻害剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤（TKI）
• プロテアソーム阻害剤
• ポリアデノシン二リン酸（ADP）リボースポリメラーゼ（PARP）阻害剤
• ラパマイシンの機構標的（mTOR）阻害剤
• 世界の分子標的治療市場遺伝子治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ウイルスベクターを用いた遺伝子治療
• 非ウイルスベクターベースの遺伝子治療
• ゲノム編集
• 世界の分子標的治療市場細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• キメラ抗原受容体T細胞療法
• T細胞受容体（TCR）療法
• 腫瘍浸潤リンパ球（TIL）療法
• 樹状細胞療法

第7章 地域別・国別分析

• 世界の分子標的治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の分子標的治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 分子標的治療市場：競合情勢
• 分子標的治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca PLC
• Amgen Inc.
• Regeneron Pharmaceuticals
• Vertex Pharmaceuticals Incorporated
• Novartis AG
• Incyte Corporation
• Exelixis Inc.
• IDEAYA Biosciences Inc.
• Prelude Therapeutics Incorporated
• Gamida Cell Ltd.
• Adaptimmune Therapeutics plc
• Engine Biosciences Pte. Ltd.
• Krystal Biotech Inc.
• Sotio Biotech a.s.
• Cybrexa Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 分子標的治療市場2029：新たな機会を提供する国
• 分子標的治療市場2029：新たな機会を提供するセグメント
• 分子標的治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Molecular targeted therapy is an advanced form of cancer treatment that works by blocking the growth and spread of cancer cells through interference with specific molecules involved in tumor development. This therapy is tailored to the genetic and molecular profile of a patient's tumor, aiming to increase treatment effectiveness while reducing damage to healthy cells. By focusing on cancer-specific pathways, it provides a more precise and less toxic alternative compared to traditional therapies.

The primary types of molecular targeted therapy include monoclonal antibodies, small-molecule inhibitors, gene therapy, and cell therapy. Monoclonal antibodies are specially engineered proteins that accurately target and eliminate cancer cells while sparing healthy tissue. This therapy is delivered through various methods such as oral, injectable, topical, and intravenous routes and is applied in the treatment of several cancers, including lung, breast, colorectal cancers, leukemia, and others. It is utilized by multiple end-users such as hospitals, clinics, research laboratories, and diagnostic centers.

The molecular targeted therapy market research report is one of a series of new reports from The Business Research Company that provides molecular targeted therapy market statistics, including the molecular targeted therapy industry global market size, regional shares, competitors with the molecular targeted therapy market share, detailed molecular targeted therapy market segments, market trends, opportunities, and any further data you may need to thrive in the molecular targeted therapy industry. This molecular targeted therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The molecular targeted therapy market size has grown strongly in recent years. It will grow from $65.78 billion in 2024 to $71.64 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth observed during the historic period was driven by factors such as the rising prevalence of chronic diseases, increasing demand for personalized medicine, greater use of biomarkers in drug development, wider adoption of monoclonal antibodies, and more oncology therapy approvals.

The molecular targeted therapy market size is expected to see strong growth in the next few years. It will grow to $99.40 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The projected growth in the forecast period is expected to be fueled by increased investment in cancer research, growing demand for targeted immunotherapies, expansion of clinical trial activities in precision medicine, rising use of companion diagnostics, and improved healthcare access in emerging markets. Key trends anticipated during the forecast period include advancements in genomics, innovations in drug delivery systems, increased funding for R&D, progress in molecular diagnostics, and the integration of AI technology in therapy discovery.

The rise of personalized medicine is expected to propel the growth of the molecular targeted therapy market going forward. Personalized medicine is a healthcare approach that customizes treatment and prevention based on an individual's genetic profile, lifestyle, and environmental factors. This approach is gaining traction due to the increasing availability of genetic data, which enables treatments tailored to individual genomes for improved efficacy and reduced side effects. Personalized medicine supports molecular targeted therapy by analyzing a patient's tumor for specific genetic mutations or biomarkers, allowing for the selection of therapies that directly target those abnormalities. This enhances treatment precision and minimizes harm to healthy tissues. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. Therefore, the rise of personalized medicine is driving the growth of the molecular targeted therapy market.

Major companies operating in the molecular targeted therapy market are focusing on developing advanced products such as small molecule inhibitors to improve patient outcomes in various cancers and chronic diseases. Small molecule inhibitors are tiny compounds capable of penetrating cells and inhibiting specific proteins that drive disease progression. For example, in January 2025, Amgen Inc., a US-based pharmaceutical company, introduced Lumakras (sotorasib) in combination with Vectibix (panitumumab), which received approval from the US Food and Drug Administration (FDA), a US-based government organization. This therapy is intended for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as confirmed by an FDA-approved test. The approval is based on the Phase 3 CodeBreaK 300 trial, which demonstrated that the combination more than doubled progression-free survival compared to the standard of care, marking the first targeted therapy to achieve such results in this chemorefractory patient group.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for approximately $43 billion. Through this acquisition, Pfizer aims to bolster its oncology portfolio and expedite the development of innovative cancer therapies by leveraging Seagen's expertise in antibody-drug conjugate (ADC) technology. Seagen Inc. is a US-based company specializing in the development of monoclonal antibody-based therapies for cancer treatment.

Major players in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

North America was the largest region in the molecular targeted therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular targeted therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the molecular targeted therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The molecular targeted therapy market consists of sales of targeted cancer drugs, kinase inhibitors, hormone therapies, and companion diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Molecular Targeted Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on molecular targeted therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for molecular targeted therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The molecular targeted therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy Type: Monoclonal Antibodies; Small Molecule Inhibitors; Gene Therapy; Cell Therapy
• 2) By Mode Of Administration: Oral; Injectable; Topical; Intravenous
• 3) By Application: Lung Cancer; Breast Cancer; Colorectal Cancer; Leukemia; Other Applications
• 4) By End-User: Hospitals; Clinics; Research Laboratories; Diagnostic Centers
• Subsegments:
• 1) By Monoclonal Antibodies: Naked Monoclonal Antibodies; Conjugated Monoclonal Antibodies; Bispecific Monoclonal Antibodies
• 2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors; Mechanistic Target Of Rapamycin (mTOR) Inhibitors
• 3) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Vector-Based Gene Therapy; Genome Editing
• 4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy; T-Cell Receptor (TCR) Therapy; Tumor-Infiltrating Lymphocytes (TILs) Therapy; Dendritic Cell Therapy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Molecular Targeted Therapy Market Characteristics

3. Molecular Targeted Therapy Market Trends And Strategies

4. Molecular Targeted Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Molecular Targeted Therapy Growth Analysis And Strategic Analysis Framework

• 5.1. Global Molecular Targeted Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Molecular Targeted Therapy Market Growth Rate Analysis
• 5.4. Global Molecular Targeted Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Molecular Targeted Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Molecular Targeted Therapy Total Addressable Market (TAM)

6. Molecular Targeted Therapy Market Segmentation

• 6.1. Global Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Small Molecule Inhibitors
• Gene Therapy
• Cell Therapy
• 6.2. Global Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Topical
• Intravenous
• 6.3. Global Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Leukemia
• Other Applications
• 6.4. Global Molecular Targeted Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Research Laboratories
• Diagnostic Centers
• 6.5. Global Molecular Targeted Therapy Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Naked Monoclonal Antibodies
• Conjugated Monoclonal Antibodies
• Bispecific Monoclonal Antibodies
• 6.6. Global Molecular Targeted Therapy Market, Sub-Segmentation Of Small Molecule Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Proteasome Inhibitors
• Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors
• Mechanistic Target Of Rapamycin (mTOR) Inhibitors
• 6.7. Global Molecular Targeted Therapy Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Vector-Based Gene Therapy
• Non-Viral Vector-Based Gene Therapy
• Genome Editing
• 6.8. Global Molecular Targeted Therapy Market, Sub-Segmentation Of Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chimeric Antigen Receptor T-Cell Therapy
• T-Cell Receptor (TCR) Therapy
• Tumor-Infiltrating Lymphocytes (TILs) Therapy
• Dendritic Cell Therapy

7. Molecular Targeted Therapy Market Regional And Country Analysis

• 7.1. Global Molecular Targeted Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Molecular Targeted Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Molecular Targeted Therapy Market

• 8.1. Asia-Pacific Molecular Targeted Therapy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Molecular Targeted Therapy Market

• 9.1. China Molecular Targeted Therapy Market Overview
• 9.2. China Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Molecular Targeted Therapy Market

• 10.1. India Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Molecular Targeted Therapy Market

• 11.1. Japan Molecular Targeted Therapy Market Overview
• 11.2. Japan Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Molecular Targeted Therapy Market

• 12.1. Australia Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Molecular Targeted Therapy Market

• 13.1. Indonesia Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Molecular Targeted Therapy Market

• 14.1. South Korea Molecular Targeted Therapy Market Overview
• 14.2. South Korea Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Molecular Targeted Therapy Market

• 15.1. Western Europe Molecular Targeted Therapy Market Overview
• 15.2. Western Europe Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Molecular Targeted Therapy Market

• 16.1. UK Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Molecular Targeted Therapy Market

• 17.1. Germany Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Molecular Targeted Therapy Market

• 18.1. France Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Molecular Targeted Therapy Market

• 19.1. Italy Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Molecular Targeted Therapy Market

• 20.1. Spain Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Molecular Targeted Therapy Market

• 21.1. Eastern Europe Molecular Targeted Therapy Market Overview
• 21.2. Eastern Europe Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Molecular Targeted Therapy Market

• 22.1. Russia Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Molecular Targeted Therapy Market

• 23.1. North America Molecular Targeted Therapy Market Overview
• 23.2. North America Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Molecular Targeted Therapy Market

• 24.1. USA Molecular Targeted Therapy Market Overview
• 24.2. USA Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Molecular Targeted Therapy Market

• 25.1. Canada Molecular Targeted Therapy Market Overview
• 25.2. Canada Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Molecular Targeted Therapy Market

• 26.1. South America Molecular Targeted Therapy Market Overview
• 26.2. South America Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Molecular Targeted Therapy Market

• 27.1. Brazil Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Molecular Targeted Therapy Market

• 28.1. Middle East Molecular Targeted Therapy Market Overview
• 28.2. Middle East Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Molecular Targeted Therapy Market

• 29.1. Africa Molecular Targeted Therapy Market Overview
• 29.2. Africa Molecular Targeted Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Molecular Targeted Therapy Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Molecular Targeted Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Molecular Targeted Therapy Market Competitive Landscape And Company Profiles

• 30.1. Molecular Targeted Therapy Market Competitive Landscape
• 30.2. Molecular Targeted Therapy Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Molecular Targeted Therapy Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Amgen Inc.
• 31.3. Regeneron Pharmaceuticals
• 31.4. Vertex Pharmaceuticals Incorporated
• 31.5. Novartis AG
• 31.6. Incyte Corporation
• 31.7. Exelixis Inc.
• 31.8. IDEAYA Biosciences Inc.
• 31.9. Prelude Therapeutics Incorporated
• 31.10. Gamida Cell Ltd.
• 31.11. Adaptimmune Therapeutics plc
• 31.12. Engine Biosciences Pte. Ltd.
• 31.13. Krystal Biotech Inc.
• 31.14. Sotio Biotech a.s.
• 31.15. Cybrexa Therapeutics Inc.

32. Global Molecular Targeted Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Molecular Targeted Therapy Market

34. Recent Developments In The Molecular Targeted Therapy Market

35. Molecular Targeted Therapy Market High Potential Countries, Segments and Strategies

• 35.1 Molecular Targeted Therapy Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Molecular Targeted Therapy Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Molecular Targeted Therapy Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer